| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| High-Throughput Nucleotide Sequencing | 11 | 2024 | 2359 | 0.840 |
Why?
|
| Mutation | 23 | 2021 | 15911 | 0.640 |
Why?
|
| Medulloblastoma | 3 | 2018 | 572 | 0.540 |
Why?
|
| Cerebellar Neoplasms | 2 | 2018 | 478 | 0.530 |
Why?
|
| Skin Neoplasms | 7 | 2019 | 4889 | 0.480 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10706 | 0.450 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1958 | 0.450 |
Why?
|
| Brain Neoplasms | 7 | 2019 | 4958 | 0.440 |
Why?
|
| Glioblastoma | 6 | 2019 | 1776 | 0.440 |
Why?
|
| Hymenoptera | 2 | 2009 | 9 | 0.420 |
Why?
|
| Neuroblastoma | 1 | 2018 | 705 | 0.410 |
Why?
|
| Circulating Tumor DNA | 3 | 2021 | 275 | 0.400 |
Why?
|
| RNA Editing | 3 | 2017 | 97 | 0.380 |
Why?
|
| DNA Copy Number Variations | 6 | 2021 | 1568 | 0.360 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1387 | 0.340 |
Why?
|
| Nesting Behavior | 1 | 2009 | 14 | 0.340 |
Why?
|
| Trehalase | 3 | 2005 | 5 | 0.290 |
Why?
|
| Inosine | 3 | 2017 | 42 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 2573 | 0.280 |
Why?
|
| Neoplasms | 10 | 2021 | 15919 | 0.280 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2664 | 0.270 |
Why?
|
| Genomics | 6 | 2021 | 2836 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2017 | 5403 | 0.270 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 5149 | 0.270 |
Why?
|
| Phthalazines | 2 | 2018 | 262 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 9041 | 0.250 |
Why?
|
| Adenosine | 3 | 2017 | 296 | 0.250 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2018 | 518 | 0.240 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 16205 | 0.230 |
Why?
|
| Benchmarking | 1 | 2024 | 275 | 0.200 |
Why?
|
| Precision Medicine | 3 | 2021 | 1208 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4961 | 0.200 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2018 | 66 | 0.200 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 184 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 3604 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2010 | 152 | 0.160 |
Why?
|
| Mucor | 2 | 2000 | 18 | 0.160 |
Why?
|
| Humans | 45 | 2024 | 270744 | 0.160 |
Why?
|
| Melanoma | 4 | 2018 | 5594 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 16669 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 183 | 0.160 |
Why?
|
| Patient Participation | 1 | 2012 | 453 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 153 | 0.150 |
Why?
|
| Prognosis | 7 | 2021 | 22480 | 0.150 |
Why?
|
| Female | 30 | 2020 | 148945 | 0.150 |
Why?
|
| Lysine | 1 | 2010 | 426 | 0.150 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2018 | 47 | 0.150 |
Why?
|
| Autophagy-Related Proteins | 1 | 2018 | 55 | 0.150 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2008 | 30 | 0.150 |
Why?
|
| Oncogenes | 1 | 2021 | 700 | 0.150 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 806 | 0.150 |
Why?
|
| Middle Aged | 23 | 2021 | 90334 | 0.150 |
Why?
|
| Hemangioma | 1 | 2019 | 157 | 0.140 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2018 | 162 | 0.140 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 14616 | 0.140 |
Why?
|
| RNA, Messenger | 3 | 2017 | 6398 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 529 | 0.140 |
Why?
|
| Computational Biology | 5 | 2024 | 1293 | 0.140 |
Why?
|
| Reproduction | 2 | 2009 | 278 | 0.140 |
Why?
|
| Adult | 20 | 2021 | 81975 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 484 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 875 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2474 | 0.130 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 221 | 0.130 |
Why?
|
| Laboratories | 1 | 2017 | 132 | 0.130 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 31006 | 0.130 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 172 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 364 | 0.130 |
Why?
|
| Heterografts | 2 | 2015 | 739 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 257 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2019 | 10385 | 0.130 |
Why?
|
| Cell Line, Tumor | 11 | 2019 | 14838 | 0.130 |
Why?
|
| Astrocytoma | 1 | 2008 | 326 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 499 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 396 | 0.130 |
Why?
|
| Aged | 17 | 2021 | 73375 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 695 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 380 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2357 | 0.120 |
Why?
|
| Decision Making | 1 | 2012 | 1251 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 383 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2021 | 1697 | 0.120 |
Why?
|
| Cadherins | 1 | 2008 | 657 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 714 | 0.120 |
Why?
|
| Genome, Human | 3 | 2019 | 1886 | 0.120 |
Why?
|
| Research | 1 | 2017 | 427 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1280 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 12028 | 0.120 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 338 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2014 | 40 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 526 | 0.120 |
Why?
|
| Protein Array Analysis | 1 | 2017 | 503 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 4480 | 0.120 |
Why?
|
| Genes, ras | 1 | 2017 | 679 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 628 | 0.110 |
Why?
|
| Cerebellum | 1 | 2018 | 471 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 130 | 0.110 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2015 | 471 | 0.110 |
Why?
|
| Fungi | 1 | 2005 | 147 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1193 | 0.110 |
Why?
|
| Histones | 1 | 2010 | 1512 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 1126 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 1442 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1579 | 0.110 |
Why?
|
| Trehalose | 2 | 2000 | 25 | 0.110 |
Why?
|
| Cell Wall | 2 | 2000 | 51 | 0.110 |
Why?
|
| Uveal Neoplasms | 1 | 2015 | 194 | 0.100 |
Why?
|
| Male | 22 | 2021 | 128374 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2021 | 1465 | 0.100 |
Why?
|
| Philadelphia Chromosome | 1 | 2016 | 852 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 551 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 4645 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2073 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 427 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 3439 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 1564 | 0.100 |
Why?
|
| Gallbladder Neoplasms | 1 | 2013 | 244 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1457 | 0.090 |
Why?
|
| Brain | 3 | 2008 | 4212 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 5171 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 1822 | 0.090 |
Why?
|
| Glioma | 2 | 2019 | 1978 | 0.090 |
Why?
|
| ras Proteins | 1 | 2015 | 804 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2453 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3919 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2019 | 7665 | 0.090 |
Why?
|
| Infant | 4 | 2018 | 13985 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 999 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 4963 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 601 | 0.090 |
Why?
|
| Gene Expression | 1 | 2008 | 3642 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 3944 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5569 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3656 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2027 | 0.080 |
Why?
|
| Piperazines | 1 | 2018 | 2145 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2017 | 2165 | 0.080 |
Why?
|
| Mice, Nude | 4 | 2015 | 4329 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3346 | 0.080 |
Why?
|
| Animals | 12 | 2017 | 62045 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 1335 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 680 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2018 | 2767 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1388 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2399 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6237 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 4795 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2017 | 2886 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2018 | 3667 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2618 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6192 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 2033 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 4048 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 1002 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15210 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2019 | 13414 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2018 | 4140 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6255 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 14012 | 0.060 |
Why?
|
| INDEL Mutation | 1 | 2024 | 114 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7894 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 5310 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2017 | 1246 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 2902 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2020 | 9290 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2016 | 3557 | 0.050 |
Why?
|
| Mice | 7 | 2017 | 35594 | 0.050 |
Why?
|
| Quality Control | 1 | 2024 | 461 | 0.050 |
Why?
|
| Adolescent | 6 | 2018 | 32735 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3215 | 0.050 |
Why?
|
| Enzyme Stability | 2 | 2005 | 110 | 0.050 |
Why?
|
| Edetic Acid | 2 | 2005 | 76 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2010 | 967 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 85 | 0.050 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2010 | 6 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2018 | 17043 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10260 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 1101 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 1825 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2005 | 606 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2018 | 9473 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2010 | 103 | 0.040 |
Why?
|
| Temperature | 2 | 2005 | 538 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5589 | 0.040 |
Why?
|
| ErbB Receptors | 2 | 2020 | 2376 | 0.040 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2009 | 18 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 24 | 0.040 |
Why?
|
| Cell Movement | 2 | 2015 | 2472 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2013 | 757 | 0.040 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2009 | 59 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 2019 | 28 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 5778 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7237 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 133 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 170 | 0.040 |
Why?
|
| Methylation | 1 | 2010 | 624 | 0.040 |
Why?
|
| Back | 1 | 2018 | 49 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 121 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 334 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 47 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 485 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 591 | 0.040 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2018 | 65 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 198 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 550 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7915 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 266 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1077 | 0.040 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2017 | 21 | 0.040 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 460 | 0.040 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2017 | 108 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 352 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 1185 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2017 | 167 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 504 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 366 | 0.030 |
Why?
|
| Child | 4 | 2018 | 30538 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 187 | 0.030 |
Why?
|
| Calibration | 1 | 2007 | 347 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1525 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 279 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 179 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 6855 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 372 | 0.030 |
Why?
|
| Algorithms | 2 | 2017 | 3900 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 322 | 0.030 |
Why?
|
| Pronase | 1 | 2005 | 8 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2018 | 636 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 676 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 1723 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2015 | 57 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 113 | 0.030 |
Why?
|
| Dasatinib | 1 | 2018 | 881 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 71 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 69 | 0.030 |
Why?
|
| DNA Primers | 1 | 2007 | 1496 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 522 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 623 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 219 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 1691 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 195 | 0.030 |
Why?
|
| Tongue Neoplasms | 1 | 2016 | 253 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 174 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 460 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 907 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1359 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 586 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2015 | 214 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 3408 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 324 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2184 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 305 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 137 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2013 | 116 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2009 | 3588 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 274 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 223 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2015 | 628 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 1273 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 2308 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 587 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 885 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33733 | 0.030 |
Why?
|
| Glucose | 2 | 2000 | 1220 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 820 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 678 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 385 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 529 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 371 | 0.030 |
Why?
|
| Young Adult | 3 | 2017 | 22216 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 754 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1267 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2017 | 5440 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 1554 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2016 | 759 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2363 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1248 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 5070 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2394 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13021 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 734 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 2455 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 5759 | 0.020 |
Why?
|
| Anaerobiosis | 1 | 2000 | 21 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 831 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 1910 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 1473 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1035 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 1569 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2000 | 259 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 3118 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 86 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 798 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 12526 | 0.020 |
Why?
|
| Proteomics | 1 | 2017 | 1427 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 5465 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 4134 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 3063 | 0.020 |
Why?
|
| DNA Damage | 1 | 2017 | 1988 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1017 | 0.020 |
Why?
|
| Culture Media | 1 | 2000 | 343 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 258 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3300 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5825 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1570 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 5437 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1401 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2170 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5102 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1960 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5060 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6686 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6447 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3478 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 4001 | 0.020 |
Why?
|
| Extracellular Space | 1 | 1997 | 148 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2602 | 0.020 |
Why?
|
| Social Behavior | 1 | 2009 | 310 | 0.020 |
Why?
|
| Cytosol | 1 | 1997 | 267 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 1840 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1997 | 378 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 6768 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4963 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 553 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2009 | 750 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2651 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7383 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1997 | 1811 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 5002 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 7754 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6516 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 5231 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 1588 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 17896 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1997 | 4943 | 0.010 |
Why?
|
| United States | 1 | 2015 | 15853 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 12102 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 39827 | 0.010 |
Why?
|